Organization
Thoracic Oncology Unit
1 abstract
Abstract
Four-year outcomes and circulating tumor DNA (ctDNA) analysis of pembrolizumab (pembro) plus concurrent chemoradiation therapy (cCRT) in unresectable, locally advanced, stage III non–small-cell lung cancer (NSCLC): From KEYNOTE-799.Org: LungenClinic, N.N. Blokhin Russian Cancer Research Center, N.N. Petrov National Medical Research Center of Oncology, Thoracic Oncology Unit, Mid North Coast Cancer Institute,